Under the Agreement the Company will Sell and Distribute Globally AXIM’s Readers and Three Novel Proprietary Tests Designed for Diagnosis…
Marks first randomized Phase 2/3 trial of CRISPR-enhanced bacteriophage precision medicineRESEARCH TRIANGLE PARK, N.C., Sept. 13, 2022 (GLOBE NEWSWIRE) --…
-Treatment with VCN-01 in combination with durvalumab demonstrated an acceptable safety profile and encouraging biological activity- ROCKVILLE, Md., Sept. 05,…
PRINCETON, N.J., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on…
Expanding services and offerings to the infectious disease community throughout the U.S. provides revenue growth opportunityServices at launch include rapid…
Glycerol monolaurate has the potential to deliver broad antimicrobial activity to treat a variety of bacterial, fungal, and viral vaginal…
GARDEN CITY, N.Y. and HAMILTON, Bermuda, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air,…
MELBOURNE, Australia, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), a commercial and clinical-stage biopharmaceutical company…
LEXINGTON, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens…
PRINCETON, N.J., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), (“Oyster Point Pharma”, or “the Company”),…